Glucose-6-phosphate dehydrogenase deficiency, the most common enzyme deficiency
worldwide, causes a spectrum of disease including neonatal hyperbilirubinemia, acute …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a prevalent condition worldwide
and is caused by loss-of-function mutations in the G6PD gene. Individuals with deficiency …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic blood
condition, can result in kernicterus at birth, and later in life as severe hemolysis on exposure …

Reproductive carrier screening started in some countries in the 1970s for
hemoglobinopathies and Tay‐Sachs disease. Cystic fibrosis carrier screening became …

A barrier to eliminating Plasmodium vivax malaria is inadequate treatment of infected
patients. 8-Aminoquinoline–based drugs clear the parasite; however, people with glucose-6 …

Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of
Plasmodium vivax, including dormant liver stages–so called hypnozoites. Its long half-life …

Background G6PD deficiency is common in malaria endemic regions and is estimated to
affect more than 400 million people worldwide. Treatment of malaria patients with the anti …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is particularly
prevalent in historically malaria-endemic countries. Although most individuals with G6PD …

The only currently available drug that effectively removes malaria hypnozoites from the
human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common metabolic disorder
affecting more than 400 million individuals worldwide. Being an X-linked disorder, the …